Actively Recruiting
IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease
Led by Children's Mercy Hospital Kansas City · Updated on 2026-01-02
15
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
C
Children's Mercy Hospital Kansas City
Lead Sponsor
I
Indiana Clinical and Translational Sciences Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying how liver congestion and fibrosis affect the way children, adolescents, and young adults with Fontan circulation process certain drugs. This investigation focuses on measuring the impact of these liver conditions on the metabolism and transport of medications in this specific group. The study is a Phase 1, open-label, single-center trial designed to gather important information on drug dosing for patients with Fontan-associated liver disease. Participants in the study will receive a single oral dose of two drugs: sildenafil and pravastatin. The dose of sildenafil varies by weight, with 10 mg given to those under 20 kg and 20 mg for those 20 kg or above. Pravastatin dosing is age-based, with 20 mg for children under 13 years and 40 mg for those 14 years or older. This dosing occurs during the assessment phase to evaluate drug concentrations and how the liver condition influences drug processing. Participants will be involved in fasting overnight before receiving the medications. Researchers will measure the concentration of sildenafil and pravastatin over a two-year period, focusing on the area under the curve (AUC) to understand drug metabolism. The study includes assessments to monitor liver function and ensure participant safety, with the total involvement spanning up to two years to capture the long-term effects on drug disposition in this population.
CONDITIONS
Brief Title
IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Older than 8 years
- Completed Fontan procedure
- Able to provide informed permission-assent if under 18, or consent if 18 or older
- Fasting overnight for about 8 hours before study participation
You will not qualify if you...
- Pregnancy
- Not fasting before the study
- Having non-removable metal in the body or any condition making MRI unsafe
- Use of sildenafil or pravastatin therapy within the past 2 months
- History or laboratory evidence of intestinal, metabolic, autoimmune, or renal disease that may affect drug processing
- Taking medications that interact with sildenafil or pravastatin
- Unable to swallow tablets
- Liver enzyme levels (AST, ALT) or bilirubin above five times the normal age-specific limits
- Diarrhea within the last 24 hours
- History of solid organ transplantation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day
Participants receive a single oral dose of sildenafil and pravastatin.
1 treatment visit (in-person)
Duration - 2 years
Participants are monitored for drug concentration and outcomes over 2 years after dosing.
Multiple visits over 2 years
Trial Site Locations
Total: 1 location
1
Children's Mercy Hospital
Kansas City, Missouri, United States, 64108
Actively Recruiting
Research Team
J
Jonthan Wagner, DO
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here